Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EPS (Weighted Average and Diluted) (2023 - 2025)

Rallybio's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at $0.36 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 238.46% year-over-year to $0.36; the TTM value through Sep 2025 reached -$0.32, up 79.87%, while the annual FY2024 figure was -$1.33, 27.72% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was $0.36 at Rallybio, up from -$0.22 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.36 in Q3 2025 and bottomed at -$0.49 in Q4 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.37 (2024), against an average of -$0.3.
  • The largest annual shift saw EPS (Weighted Average and Diluted) dropped 9.3% in 2024 before it soared 238.46% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.49 in 2023, then surged by 48.98% to -$0.25 in 2024, then soared by 244.0% to $0.36 in 2025.
  • Per Business Quant, the three most recent readings for RLYB's EPS (Weighted Average and Diluted) are $0.36 (Q3 2025), -$0.22 (Q2 2025), and -$0.21 (Q1 2025).